The United States Patent Trial and Appeal Board (PTAB) has denied biosimilar developer Samsung Bioepis’ request for inter partes review (IPR) of a patent that Genentech holds covering reference trastuzumab (Herceptin).
The United States Patent Trial and Appeal Board (PTAB) has denied biosimilar developer Samsung Bioepis’ request for inter partes review (IPR) of a patent that Genentech holds covering reference trastuzumab (Herceptin).
This is not the first time that the board has denied a claim for review of US Patent Number 7,846,441. Previously, Hospira, owned by Pfizer, and Celltrion had also petitioned PTAB to the Genentech patent in January 2017. Initially, the PTAB denied the review, but later reversed the decision after finding that Hospira had shown each of the patent’s claims were likely invalid.
Celltrion filed its own challenge in March 2017, in which PTAB had instituted an IPR, which Hospira subsequently joined.
Samsung Bioepis had stated that Genentech’s claim was obvious, based, in part, on a research paper. The same paper had been cited in both prior claims from Celltiron and Hospira.
In the board's denial of Samsung Bioepis’ request for an IPR proceeding, it explained that Samsung Bioepis’ evidence brought nothing new to the table. The research paper that had been cited in the 2 prior claims was cited in an additional reference provided by Samsung Bioepis, and that reference was cited by yet another. “In other words, Bioepis’ arguments on the newly asserted references are substantially the same as those in the earlier cases,” said the board.
According to Genentech, this particular paper was also considered in the prosecution of the patent. “Thus, after considering the totality of the circumstances, we agree with [Genentech] that it is appropriate for us to exercise our discretion to deny the petition under 35 USC § 325(d),” stated the board.
Although the outcome was favorable for Genentech, the pharma company is taking steps to further protect its drug from competitors and has recently indicated plans to seek injunctions to stop Samsung Bioepis from selling its biosimilar trastuzumab in Europe.
Genentech has requested US District Judge Robert Sweet to order Samsung Bioepis’ counsel, White & Case LLP, to share parts of its abbreviated Biologics License Application to examine certain chemical properties of the proposed trastuzumab biosimilar.
According to White & Case, Genentech is not entitled to receive this information from the European Medicines Agency and is “fishing” for grounds to challenge the biosimilar. The judge has yet to rule.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.